Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

NCT03207438 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1790

Enrollment

OTHER

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

DRUG: Quetiapine 50 MG Extended Release Oral Tablet
DRUG: Quetiapine Fumarate XR 150-300 mg
DRUG: Placebos

Sponsor

University of Saskatchewan

Collaborators

[object Object]